Researchers have formed one easy blood test that can help in detecting when a recently transplanted lung is being refused by a patient. This test is unique as it can be helpful even when no outward symptoms of this rejection are apparent. The latest test might make it possible for doctors to intervene rapidly to avoid or slow down the supposed chronic rejection. This rejection can be irreversible, severe, and often fatal, in those foremost critical months after the lung transplantation procedure.
Researchers suppose this test might be helpful to monitor the rejection in other organ transplants as well. This work was backed by the National Heart, Lung, and Blood Institute (NHLBI), which is the section of the National Institutes of Health. The study’s results are planned to be published in the journal EBioMedicine. Hannah Valantine, M.D., is the co-leader of the research.
On a similar note, researchers from the University College London (UCL) came into the news as they disclosed that they have assessed the application of molecular profiling. This profiling is employed to forecast lung cancer by studying precancerous lesions. According to earlier studies, just 50% of precancerous lesions in the airway grow into lung cancer, while the remaining are found to be benign or they disappear.
These lesions look identical under a microscope, making it tricky for doctors to schedule treatments. In the latest research, the scientists spotted differences between the lesions that convert into cancer and those that are undamaging. For this, researchers performed a study of their molecular profile. They carried out the methylation profiling, gene expression profiling, and whole-genome DNA sequencing on almost 129 pre-invasive lung cancer lesion biopsies from about 85 cancer patients.
In addition, these patients were subjected to over 5 Years of follow-up after completion of the biopsy procedure. Dissimilarities in genomic features such as gene expression, mutations, and chromosomal unsteadiness were recognized, paving the way for trials that could forecast lesions that might lead to cancer.